<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608137</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00062-53</org_study_id>
    <nct_id>NCT03608137</nct_id>
  </id_info>
  <brief_title>Cannabis and Thought Disorder in Schizophrenia</brief_title>
  <acronym>CANDI</acronym>
  <official_title>Cannabis and Thought Disorder in Schizophrenia: Clinical and Neuroimaging Relationships</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have suggested a strong relationship between cannabis use and the level of
      thought disorder in subjects with schizophrenia. Moreover, the level of thought disorder has
      been associated with an increased functional connectivity between the temporal lobe and the
      Putamen. However, the brain mechanisms underlying these two relationships are still poorly
      known. Better understanding these mechanisms is important to improve patients' care, in
      particular among treatment-resistant patients.

      The objective of the CANDI study consists of assessing whether the level of cannabis use in
      patients with schizophrenia modulates the level of thought disorder via a modulation of the
      functional connectivity between the temporal lobe and the Putamen. Analyses will be
      controlled for the composition of cannabis, in particular the tetrahydrocannabinol /
      cannabidiol ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      25 subjects with schizophrenia and current cannabis use will be recruited in the experimental
      group. The control group will consist of 25 subjects with schizophrenia but with no cannabis
      use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of thought disorder</measure>
    <time_frame>one year</time_frame>
    <description>The level of thought disorder will be investigated using the specific items of the Positive And Negative Syndrome Scale (PANSS; Kay et al., 1987) Minimum score 1 Maximum score 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cannabis use</measure>
    <time_frame>one year</time_frame>
    <description>cannabis use (yes vs. no; i.e., the group factor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta-9 tetrahydrocannabinol (THC) concentration</measure>
    <time_frame>one year</time_frame>
    <description>Concentrations of Delta-9 tetrahydrocannabinol in the cannabis usually smoked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabidiol (CBD) concentration</measure>
    <time_frame>one year</time_frame>
    <description>Concentration of cannabidiol in the cannabis usually smoked</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non- cannabis users (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships</intervention_name>
    <description>To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.</description>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Non- cannabis users (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 65

          -  Meeting the DSM-5 criteria for schizophrenia

          -  &quot;Cannabis user&quot; group: - Smoking at least two days per week during the previous months

          -  Displaying positive urine screen for cannabis

          -  &quot;Non-cannabis user&quot; group: - No episode of cannabis smoking during the previous month

          -  Negative urine screen for cannabis + no lifetime criteria for cannabis use disorder
             (assessment by an addiction specialist).

        Exclusion Criteria:

          -  Current criteria for axis-1 psychiatric disorder other than schizophrenia

          -  Current criteria for any other substance use disorder except for nicotine use disorder

          -  Any contraindication for MRI

          -  Tutorship or curatorship

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin ROLLAND, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH LE VINATIER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume SESCOUSSE, MD</last_name>
    <role>Study Director</role>
    <affiliation>CH LE VINATIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin ROLLAND, MD, PhD</last_name>
    <phone>+33 437 915 555</phone>
    <email>benjamin.rolland@ch-le-vinatier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronique VIAL</last_name>
    <phone>0033437915531</phone>
    <email>veronique.vial@ch-le-vinatier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Le Vinatier</name>
      <address>
        <city>Bron</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>69678 cedex</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROLLAND BENJAMIN, MD,Ph</last_name>
      <phone>0033 437 915 555</phone>
      <email>benjamin.rolland@ch-le-vinatier.fr</email>
    </contact>
    <contact_backup>
      <last_name>VIAL VERONIQUE</last_name>
      <phone>0033 437 915 531</phone>
      <email>veronique.vial@ch-le-vinatier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia ; Cannabis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

